Results 171 to 180 of about 1,963 (217)

Efficacy of Salmeterol Xinafoate Powder in Children With ChronicPersistent Asthma

Pediatrics, 1999
Rama Yerramsetti, Stanley P. Galant
openalex   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Control of the Physical Form of Salmeterol Xinafoate

Organic Process Research & Development, 1999
Two approaches to the generation of particles of the phenethanolamine, salmeterol xinafoate, are discussed. To produce particles with good flow properties a fast cooling crystallisation process was developed which delivered salmeterol xinafoate as spherical agglomerates of microcrystals which had good powder flow characteristics and could be micronised
Steve Beach, David Latham, Colin Sidgwick, Mazen Hanna, Peter York   +4 more
openaire   +1 more source

Efficacy of salmeterol xinafoate in horses with recurrent airway obstruction

Journal of the American Veterinary Medical Association, 2001
Abstract Objective—To determine the onset, magnitude, and duration of bronchodilation after administration of aerosolized salmeterol xinafoate in horses with recurrent airway obstruction. Design—Randomized controlled study Animals—6 horses with recurrent airway obstruction.
S L, Henrikson, B R, Rush
openaire   +2 more sources

Formulating powder–device combinations for salmeterol xinafoate dry powder inhalers

International Journal of Pharmaceutics, 2015
Using salmeterol xinafoate (SX) as an active pharmaceutical ingredient, the effects of carrier lactose particle type, total lactose fines content and device resistance on dry powder inhaler performance were investigated in vitro. To mimic drug levels in commercial preparations, interactive mixtures containing 0.58% w/w SX were prepared by low shear ...
Hassoun, Mireille, Ho, Shirlene, Muddle, Joanna, Parry, Mark, Hammond, Mark, Forbes, Ben, BUTTINI, Francesca   +6 more
openaire   +3 more sources

Characterization of Two Polymorphs of Salmeterol Xinafoate Crystallized From Supercritical Fluids

Pharmaceutical Research, 2001
To characterize two polymorphs of salmeterol xinafoate (SX-I and SX-II) produced by supercritical fluid crystallization.SX-I and SX-II were crystallized as fine powders using Solution Enhanced Dispersion by Supercritical Fluids (SEDS). The two polymorphs and a reference micronized SX sample (MSX) were characterized using powder X-ray diffractometry ...
Tong, HHY, Shekunov, BY, York, P., Chow, AHL   +3 more
openaire   +3 more sources

Efficacy of Salmeterol Xinafoate Powder in Children with Chronic Persistent Asthma

Annals of Allergy, Asthma & Immunology, 1998
The efficacy and safety of salmeterol powder have not previously been evaluated in children with asthma in the United States.The efficacy and safety of salmeterol powder versus placebo were compared in children between the ages of 4 and 11 years with chronic persistent asthma.A randomized, double-blind, placebo-controlled, parallel group trial was ...
S F, Weinstein, D S, Pearlman, E A, Bronsky, A, Byrne, T, Arledge, R, Liddle, E, Stahl   +6 more
openaire   +2 more sources

Salmeterol Xinafoate in Asthma

JAMA: The Journal of the American Medical Association, 1994
To the Editor. —Dr Bone 1 highlighted some important points regarding the indicated uses of salmeterol xinafoate, a new long-acting inhaled bronchodilator. This selective β 2 -adrenoceptor agonist is intended for use twice daily as a maintenance therapy and, based on a relatively slower onset of action than short-acting β 2 -adrenoceptor agonists ...
openaire   +1 more source

Salmeterol Xinafoate in Asthma-Reply

JAMA: The Journal of the American Medical Association, 1994
In Reply. —My Editorial notes that salmeterol provides more effective bronchodilation than albuterol in patients requiring maintenance therapy for asthma. The Editorial, however, goes on to state that salmeterol should not be used more than twice daily at recommended doses. The drug is approved only for use this way. The package insert 1 for Serevent (
openaire   +1 more source

Disposition of salmeterol xinafoate in laboratory animals and humans.

Drug Metabolism and Disposition, 1993
The disposition of [14C]salmeterol xinafoate, a new inhaled beta 2-adrenoceptor agonist with both bronchodilator and antiinflammatory activity, has been studied in laboratory animals and humans following intravenous and oral administration. [14C]Salmeterol was rapidly absorbed in animal species and humans with Cmax observed within 2 hr.
G R, Manchee, A, Barrow, S, Kulkarni, E, Palmer, J, Oxford, P V, Colthup, J G, Maconochie, M H, Tarbit   +7 more
openaire   +2 more sources

Comparison of salmeterol xinafoate microparticle production by conventional and novel antisolvent crystallization

European Journal of Pharmaceutics and Biopharmaceutics, 2008
The production of microparticles for inhalation has relied on jet-milling while the potential for crystallization of microparticles has remained underexplored until relatively recently. Aqueous antisolvent crystallization of salmeterol xinafoate (SX) from poly(ethylene glycol) (PEG) and other organic (co)solvent systems was compared in order to ...
Darragh, Murnane, Christopher, Marriott, Gary P, Martin   +2 more
openaire   +2 more sources